Vulinacimab (Anti-VEGFR2 / KDR / CD309)

Synonyms: HLX-06

Catalog No.A3110 Purity:≥99%

Vulinacimab (Anti-VEGFR2 / KDR / CD309) is a monoclonal antibody targeting VEGFR-2. It has potential anti-angiogenesis and antineoplastic activities and can be used in the research of cancers. MW :145.38 KD.

Purity & Quality Control

≥99

Choose Selective VEGFR Inhibitors

Name	Citation	VEGFR1	VEGFR2	VEGFR3	Others
Foretinib	93	+++	++++	++++	Met,Tie-2,RON
Cediranib (AZD2171)	66	+++	++++	++++	c-Kit,PDGFRβ,FGFR1
PD173074	120		+		FGFR1
Dovitinib (TKI-258)	49	+++	+++	+++	FLT3,c-Kit,FGFR1
Linifanib (ABT-869)	32	++++	++++	+	CSF-1R,FLT3,Kit
Vatalanib (PTK787) 2HCl	51	+	++	+	PDGFRβ,c-Kit,c-Fms
RAF265 (CHIR-265)	23		++		B-Raf
Motesanib Diphosphate (AMG-706)	12	++++	++++	+++	Kit,RET,PDGFR
Brivanib (BMS-540215)	9	+	++		FGFR1
MGCD-265 analog	12	++++	++++	++++	Met,RON,Tie-2
AEE788 (NVP-AEE788)	13	+	+		EGFR,HER2/ErbB2,c-Abl
ENMD-2076	8		+	++	FLT3,RET,Aurora A
OSI-930	7	+++	+++		CSF-1R,LCK,C-Raf
CYC116	10		++		Aurora A,Aurora B,FLT3
Ki8751	20		++++		c-Kit,PDGFRα
Telatinib	5		+++	++++	c-Kit,PDGFRα
KRN 633	6	+	+	+	PDGFRα,c-Kit,BTK
SAR131675	30			++
Apatinib (YN968D1) mesylate	23		++++		RET
BMS-794833	1		++		Met
Brivanib Alaninate (BMS-582664)	2	+	++		FGFR1
Golvatinib (E7050)	8		++		c-Met
Semaxanib (SU5416)	19		+
ZM 323881 HCl	17		++++
ZM 306416	13	+			Src,Abl
Sitravatinib (MGCD516)	3	+++	+++	++++	DDR2,EPHA3,Axl
BFH772	0		++++
BAW2881 (NVP-BAW2881)	2	+	+++	+	C-Raf-1,B-RAFV599E,c-Abl
SU5402	17		++		FGFR1,PDGFRβ
Dovitinib (TKI258) Lactate monohydrate	30	+++	+++	+++	FLT3,c-Kit,FGFR1
LY2874455	14		+++		FGFR2,FGFR1,FGFR4
SKLB1002	4		++
AZD2932	3		+++		PDGFRβ,Flt3,c-Kit

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Biological Activity

Description	Vulinacimab (Anti-VEGFR2 / KDR / CD309) is a monoclonal antibody targeting VEGFR-2. It has potential anti-angiogenesis and antineoplastic activities and can be used in the research of cancers. MW :145.38 KD.

References
[1] https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C156172

References

[1] https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C156172

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	2250342-36-8
Isotype	Human IgG1
Source	CHO
Formulation	100mMPro-Ac,20mMArg-Ac，pH5.0
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

* Name Please enter your name.

* Email Please enter your email. Please enter a valid email address.

Phone

* Comments: Please write something to us.

Tags: buy Vulinacimab (Anti-VEGFR2 / KDR / CD309) | Vulinacimab (Anti-VEGFR2 / KDR / CD309) supplier | purchase Vulinacimab (Anti-VEGFR2 / KDR / CD309) | Vulinacimab (Anti-VEGFR2 / KDR / CD309) cost | Vulinacimab (Anti-VEGFR2 / KDR / CD309) manufacturer | order Vulinacimab (Anti-VEGFR2 / KDR / CD309) | Vulinacimab (Anti-VEGFR2 / KDR / CD309) distributor